Bristol-Myers Squibb Company (BVMF:BMYB34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 602.20B +4.5% |
| Revenue (ttm) | 252.92B +1.8% |
| Net Income | 37.95B +34.3% |
| EPS | 18.63 +33.7% |
| Shares Out | n/a |
| PE Ratio | 15.87 |
| Forward PE | 9.44 |
| Dividend | 8.26 (2.83%) |
| Ex-Dividend Date | Apr 2, 2026 |
| Volume | 4 |
| Average Volume | 8 |
| Open | 292.02 |
| Previous Close | 274.97 |
| Day's Range | 292.02 - 292.02 |
| 52-Week Range | 227.85 - 337.49 |
| Beta | 0.26 |
| RSI | 47.71 |
| Earnings Date | Apr 30, 2026 |
About BVMF:BMYB34
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat ... [Read more]
News
BMY Stock Rises as Bristol Myers Brings Anthropic’s Claude AI to 30,000 Employees
Bristol Myers Squibb ($BMY), a large U.S. drug firm focused on cancer, blood, and immune disease drugs, is teaming up with Anthropic to bring its Claude AI model to more…
Bristol Myers to deploy Anthropic's Claude AI model to speed up drug discovery
Bristol Myers Squibb said on Wednesday it is partnering with Anthropic to make its Claude AI model available to over 30,000 employees in an effort to accelerate the discovery, development and delive...
Bristol Myers announces strategic agreement with Anthropic
Bristol Myers (BMY) Squibb announced a strategic agreement with Anthropic to deploy Claude across the company’s research, clinical development, manufacturing, commercial, and corporate functions. The ...
Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global Operations
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across.
Bristol-Myers Squibb Brings Anthropic's Claude to 30,000 of Its Staff
The deal helps solidify Anthropic's commitment to the life sciences sector as it targets more enterprise clients.
US Supreme Court rebuffs pharma challenge to Biden-era drug price
The U.S. Supreme Court declined on Monday to hear a pharmaceutical industry challenge to a plan to curb Medicare drug prices adopted during Democratic former President Joe Biden's administration that...
Bristol Myers Squibb turns to China to develop new drugs in newest cross-continent collaboration
Bristol Myers Squibb this week announced a partnership with Hengrui Pharma to develop drugs together. American and European biopharmaceutical companies are increasingly looking to China for their next...
Bristol-Myers Squibb Company Transcript: Bank of America Global Healthcare Conference 2026
Strong growth in the portfolio is driven by new launches and robust pipeline progress, with double-digit gains in key products and multiple catalysts expected through 2030. Strategic business development and innovation in oncology, neuroscience, and cardiovascular therapies position the company for sustained leadership.
Tempus AI announces strategic collaboration with Bristol Myers
Tempus AI (TEM) announced a new initiative with Bristol Myers Squibb (BMY). This collaboration aims to leverage AI, multimodal real-world data and data science techniques to optimize clinical trial de...
Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new initiative with Bristol Myers Squibb (NYSE...
Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees
Highlights Nominees' Robust Skillsets and Extensive Experience in Healthcare and Biopharmaceuticals Urges Stockholders to Vote “ FOR ” the Election of Pacira's Highly Qualified Nominees on the BLUE Pr...
Bristol-Myers Squibb and China's Hengrui Pharma Forge Tie-Up
U.S. pharmaceutical giant Bristol-Myers Squibb has struck a strategic partnership and licensing deal with major Chinese drugmaker Hengrui Pharmaceuticals, in a deal that could worth more than $15 bill...
Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology
Landmark collaboration leverages complementary capabilities to drive speed in early innovation and help advance medicines for patients worldwide Agreements include 13 programs with the potential to ad...
China's Jiangsu Hengrui, Bristol Myers Squibb in deal worth up to $15.2 bln
China's Jiangsu Hengrui Pharmaceuticals said on Tuesday it has struck global strategic collaboration and licensing deal with U.S. drugmaker Bristol Myers Squibb to develop 13 early‑stage on...
Bristol Myers Squibb Touts Pipeline Gains as Shareholders Back Board at Annual Meeting
Bristol Myers Squibb NYSE: BMY used its 2026 annual meeting of shareholders to highlight progress in its growth portfolio, pipeline development, balance sheet management and cost-saving initiatives, w...
Bristol Myers announces EU approved Sotyktu to treat PsA
Bristol Myers (BMY) Squibb announced that the European Commission has granted approval to Sotyktu, or deucravacitinib, alone or in combination with methotrexate, for the treatment of active psoriatic ...
Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #POETYK--Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults.
Bristol Myers using AI to boost drug production volume, NY Times reports
Bristol Myers (BMY)’ Massachusetts facility boosted drug production volume for clinical and commercial use by about 40% with AI, The New York Times’ Farah Stockman reports. “We are able to…
Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026.
Bristol-Myers Squibb Company Transcript: AGM 2026
The meeting reviewed strong 2025 financials, highlighted a robust growth portfolio, and outlined strategic investments in AI and acquisitions. All board proposals passed with high support, while a shareholder proposal for an independent chair was rejected. Patent cliffs and stock underperformance were key risks discussed.
Bristol Myers Squibb Launches “Won't Lose” Media Campaign Ahead of FIFA World Cup 2026™
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Launches "Won't Lose" Media Campaign Ahead of FIFA World Cup 2026™.
Big Pharma M&A set for mega year as patent expiries drive deal urgency
Biotech dealmaking is on pace for a bumper year in 2026, with large drugmakers on an acquisition spree to boost their pipelines ahead of upcoming patent losses.
Bristol Myers price target raised to $66 from $64 at Citi
Citi raised the firm’s price target on Bristol Myers (BMY) to $66 from $64 and keeps a Neutral rating on the shares. The firm updated the company’s model post the…
Bristol-Myers Squibb Company Earnings Call Transcript: Q1 2026
Q1 2026 saw 1% revenue growth to $11.5B, with a 9% rise in the growth portfolio and strong launches for key assets. Pipeline advanced with regulatory milestones and positive pivotal data, while guidance was reaffirmed and performance is tracking toward the upper end of ranges.
Bristol-Myers Squibb Company Earnings release: Q1 2026
Bristol-Myers Squibb Company released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.